Medicina
Departamento
Université Catholique de Louvain
Louvain-la-Neuve, BélgicaPublicaciones en colaboración con investigadores/as de Université Catholique de Louvain (39)
2024
2023
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
-
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
The Lancet, Vol. 401, Núm. 10370, pp. 49-59
2022
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
-
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology, Vol. 32
-
Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance
Clinical Nutrition, Vol. 41, Núm. 12, pp. 2869-2886
-
Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection
JAMA Cardiology, Vol. 7, Núm. 2, pp. 159-166
2021
-
A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline
Leukemia, Vol. 35, Núm. 11, pp. 3295-3298
-
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
ESMO Open, Vol. 6, Núm. 5
-
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297
-
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
European Urology, Vol. 80, Núm. 4, pp. 497-506
-
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
The Lancet Infectious Diseases, Vol. 21, Núm. 9, pp. 1313-1323
-
Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe
Journal of travel medicine, Vol. 28, Núm. 4
-
MPL S505C enhances driver mutations at W515 in essential thrombocythemia
Blood Cancer Journal
2020
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
European Respiratory Journal, Vol. 55, Núm. 1
-
Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients
Journal of Crohn's and Colitis, Vol. 14, Núm. 4, pp. 480-489
-
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525
-
Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial
Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197
-
Toll-like receptor 3 increases antigen-presenting cell responses to a pro-apoptotic stimulus, yet does not contribute to systemic lupus erythematosus genetic susceptibility
Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 881-890
2019
-
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
New England Journal of Medicine, Vol. 381, Núm. 26, pp. 2506-2518